AX 1604 - Axim Biotech
Alternative Names: AX-1604Latest Information Update: 28 Dec 2019
At a glance
- Originator Axim Biotech
- Class Antipsychotics; Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psychotic disorders
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Psychotic-disorders in USA (Buccal, Gum)
- 19 Mar 2018 Axim Biotech plans clinical trials for Psychotic disorders in Canada
- 16 Nov 2016 Axim Biotech receives patent allowance for cannabinoid-containing controlled-release chewing gum products in USA